Bayer Sees Opportunity With $300M Acquisition of Eye Drug BiotechNews DeskMay 6, 20260 Bayer is paying $300 million to buy Perfuse Therapeutics, a clinical-stage biotech that offers a new growth opportunity in ophthalmology…